FDA Still Soliciting Applications For START Pilot As Deadline For Rare Disease Program Looms

Agency anticipated receiving more applications for the program, which aims to bring Operation Warp Speed-like response to investigational rare disease therapies, than it has so far, though a last-minute ‘flood’ is still expected. CBER and CDER are accepting requests through 1 March.

Crossing finish line
FDA pilot program aims to get rare disease treatments across the finish line faster • Source: Shutterstock

The US Food and Drug Administration will soon be selecting sponsors to participate in its Support for clinical Trials Advancing Rare disease Therapeutics (START) pilot program, which is intended to speed up the development of novel drug and biological products to treat rare diseases, but competition for the slots may not be as intense as initially anticipated.

Sponsors can submit an amendment to their investigational new drug application requesting to participate in the program from 2 January...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Rare Diseases

EMA Backs Insmed’s Brinsupri And Sanofi’s Wayrilz, Rejects Rezurock

 

The European Medicines Agency’s human medicines committee, the CHMP, has recommended Insmed’s Brinsupri and Sanofi’s Wayrilz for pan-EU approval but turned down Sanofi’s Rezurock based on trial results that cast doubt on the drug’s efficacy.

EMA Targets Consistency In Trials For Idiopathic Pulmonary Fibrosis Drugs

 
• By 

The European Medicines Agency makes a case for developing the first EU-wide guideline to clarify regulatory expectations for idiopathic pulmonary fibrosis medicines, with a focus on standardizing outcome measures and trial design.

EU Decision Time For Insmed’s Brensocatib And Sanofi’s Belumosudil

 

Insmed’s first-in-class bronchiectasis drug, brensocatib, is among the products that are up for an opinion by the European Medicines Agency’s human medicines committee this week on whether they should be approved for use in the EU.

EMA Mapping RWD Landscape To Bridge Evidence Gap For Duchenne Drugs

 
• By 

A new EU study will assess the potential of existing Duchenne muscular dystrophy patient registries and other real-world data sources to address regulatory questions for emerging therapies.

More from Pink Sheet

Initial Medicare Price Offer For Ozempic, Wegovy Almost Half Off Net, Analysis Suggests

 
• By 

Only Bausch Health’s Xifaxan may have had a lower initial offer among the 15 drugs in the current Medicare price negotiation round, researchers at the University of Washington and the University of California, San Diego, projected.

Industry Rethinking Visual Elements And Quality-Of-Life Claims After US FDA Drug Ad Crackdown

 
• By 

Sponsors should consider whether their TV commercials contain the same number of scene changes during the major statement as ads that received a violation letter.

Gene Therapy Sponsors Seek More US FDA ‘Platform’ Guidance, Offer Master File Idea

 

One clear message from a US FDA listening session on leveraging knowledge across cell and gene therapy products is sponsors want more guidance on how the FDA’s new platform therapy pathway will function.